Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Revenue (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Revenue for 16 consecutive years, with $590000.0 as the latest value for Q4 2025.

  • Quarterly Revenue rose 58900.0% to $590000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $767000.0 through Dec 2025, up 10857.14% year-over-year, with the annual reading at $767000.0 for FY2025, 10857.14% up from the prior year.
  • Revenue hit $590000.0 in Q4 2025 for Guided Therapeutics, up from $60000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $590000.0 in Q4 2025 to a low of $1000.0 in Q4 2024.
  • Historically, Revenue has averaged $69000.0 across 5 years, with a median of $20500.0 in 2021.
  • Biggest five-year swings in Revenue: crashed 96.88% in 2024 and later surged 58900.0% in 2025.
  • Year by year, Revenue stood at $60000.0 in 2021, then tumbled by 95.0% to $3000.0 in 2022, then soared by 966.67% to $32000.0 in 2023, then plummeted by 96.88% to $1000.0 in 2024, then soared by 58900.0% to $590000.0 in 2025.
  • Business Quant data shows Revenue for GTHP at $590000.0 in Q4 2025, $60000.0 in Q3 2025, and $117000.0 in Q2 2025.